ArticleBMC psychiatry2026
Cumulative anticholinergic burden is associated with lower clozapine metabolic ratios: a cross-sectional study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClozapine is the most effective treatment for treatment-resistant schizophrenia, yet substantial interindividual variability in serum concentrations complicates dose optimization and therapeutic drug monitoring. While factors such as smoking and inflammation are known to influence clozapine metabolism, a substantial portion of the variability remains unexplained. Anticholinergic burden, reflecting cumulative exposure to anticholinergic medications, may be a clinically relevant yet underexplored factor associated with pharmacokinetic variability.
methodsThis retrospective cross-sectional study included 93 patients diagnosed with schizophrenia spectrum and other psychotic disorders according to DSM-5 and receiving clozapine treatment at a tertiary psychiatric center. Serum clozapine and norclozapine concentrations were obtained under routine clinical conditions and used to calculate clozapine metabolic ratios, including the concentration-to-dose (C/D) ratio (serum concentration divided by daily dose) and the clozapine/norclozapine (C/N) ratio (serum clozapine concentration divided by serum norclozapine concentration). Anticholinergic burden was quantified using the Anticholinergic Cognitive Burden calculator. Clinical variables, including age, sex, smoking status, C-reactive protein, and neutrophil-to-lymphocyte ratio, were extracted from medical records. Associations between clinical variables and clozapine metabolic ratios were assessed using Spearman correlation analyses, and factors independently associated with metabolic ratios were identified using multivariate linear regression models.
resultsThe mean anticholinergic burden score was 2.67 ± 2.02, and 52.7% of patients had clinically significant anticholinergic burden (≥ 3). Higher anticholinergic burden was significantly associated with lower concentration-to-dose (r = - 0.349, p = 0.001) and clozapine/norclozapine ratios (r = - 0.429, p < 0.001). In multivariate regression analyses, anticholinergic burden remained independently associated with lower clozapine/norclozapine (β = -0.400, p < 0.001) and concentration-to-dose ratios (β = -0.334, p = 0.001). Smoking was independently associated with lower concentration-to-dose ratio (β = -0.230, p = 0.038), but not with clozapine/norclozapine ratio. Other variables, including age, sex, C-reactive protein abnormality, and neutrophil-to-lymphocyte ratio, were not significant predictors.
conclusionsCumulative anticholinergic burden was independently associated with lower clozapine metabolic ratios in routine clinical practice. These findings suggest that anticholinergic burden may serve as a clinically accessible and practical indicator associated with variability in clozapine exposure and may aid in the interpretation of therapeutic drug monitoring. Further prospective studies are needed to clarify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.